Meeting
2021 ASCO Annual Meeting
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
Authors
Kensei Yamaguchi
The Cancer Institute Hospital of JFCR, Tokyo, Japan
Kensei Yamaguchi , Yung-Jue Bang , Satoru Iwasa , Naotoshi Sugimoto , Min-Hee Ryu , Daisuke Sakai , Hyun Cheol Cheol Chung , Hisato Kawakami , Hiroshi Yabusaki , Jeeyun Lee , Kaku Saito , Yoshinori Kawaguchi , Takahiro Kamio , Akihito Kojima , Masahiro Sugihara , Kohei Shitara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03329690
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4048)
DOI
10.1200/JCO.2021.39.15_suppl.4048
Abstract #
4048
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
First Author: Kohei Shitara
Poster
2019 Gastrointestinal Cancers Symposium
![A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.](https://d201v5jt9ylckg.cloudfront.net/235/14138/168794/168794_poster_pv.jpg)
A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
First Author: Kohei Shitara
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
First Author: Takayuki Yoshino
Poster
2018 ASCO Annual Meeting
A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
First Author: Kensei Yamaguchi